Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | MTOR | P42345 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18807465 | 0.84 | MTOR (0.52) | DYRK1AMTOR | |
| SCHEMBL12376167 | 0.83 | MTOR (0.58) | DYRK1AMAPTMTORSMN1; SMN2GAA | |
| SCHEMBL28629509 | 0.80 | AURKB (0.60) | MAPTMTORSMN1; SMN2GAAPAX8 | |
| SCHEMBL15615899 | 0.80 | MTOR (0.46) | MAPTMTORSMN1; SMN2 | |
| SCHEMBL16086154 | 0.80 | MTOR (0.43) | DYRK1AMTOR | |
| SCHEMBL14978583 | 0.80 | MTOR (0.44) | MTOR | |
| SCHEMBL31439307 | 0.78 | MTOR (0.47) | MTOR | |
| SCHEMBL15747836 | 0.78 | MTOR (0.47) | MTOR | |
| SCHEMBL17031568 | 0.78 | AURKB (0.57) | DYRK1AMAPTSMN1; SMN2GAATP53 | |
| SCHEMBL15615882 | 0.78 | MAPT (0.52) | DYRK1AMAPTSMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2896622-B1 | PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2017-05-03 | — | — | EP | disclosed |
| EP-2896622-B1 | PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2017-05-03 | — | — | EP | disclosed |
| US-9475812-B2 | Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use | Xuanzhu Pharma Co., Ltd. (CN) | 2016-10-25 | — | — | US | disclosed |
| US-9475812-B2 | Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use | Xuanzhu Pharma Co., Ltd. (CN) | 2016-10-25 | — | — | US | disclosed |
| US-9365572-B2 | PI3K and/or mTOR inhibitor | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-14 | — | — | US | disclosed |
| US-9365572-B2 | PI3K and/or mTOR inhibitor | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-14 | — | — | US | disclosed |
| EP-2781520-B1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2016-05-04 | — | — | EP | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-9284315-B2 | Three-ring PI3K and/or mTOR inhibitor | ZUANZHU PHARMA CO., LTD. (CN) | 2016-03-15 | — | — | US | disclosed |
| US-20150239885-A1 | PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-08-27 | — | — | US | disclosed |
| EP-2896622-A1 | PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-07-22 | — | — | EP | disclosed |
| EP-2896622-A1 | PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-07-22 | — | — | EP | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-06-18 | — | — | US | disclosed |
| WO-2014154026-A1 | PI3K AND/OR mTOR INHIBITOR PRODRUG | 山东轩竹医药科技有限公司 (CN) | 2014-10-02 | — | — | WO | disclosed |
| EP-2781520-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014040373-A1 | PI3K AND/OR MTOR INHIBITOR | 山东轩竹医药科技有限公司 (CN) | 2014-03-20 | — | — | WO | disclosed |
| WO-2013071698-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | 山东轩竹医药科技有限公司 (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166539-A1 | THREE-RING PI3K AND/OR MTOR INHIBITOR | MTOR, RICTOR, AKT3 | DYRK1A 995/4885MAPT 2952/4885MTOR 1/4885 |
| US-20150239885-A1 | PI3K AND/OR MTOR INHIBITOR | MTOR, RICTOR, RPTOR | DYRK1A 826/4885MAPT 2500/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.